EMA 401 has Phase II success for Post Herpetic Neuralgia

There have been positive headline results from the Phase II clinical trial of EMA 401 from Spinifex Pharmaceuticals, in Postherpetic Neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals. The clinical trial met its primary endpoint, reduction in mean daily pain score versus placebo over the last week of 28 days of treatment. Results show a statistically significant and clinically meaningful reduction in mean pain intensity from baseline to week 4 for subjects on active treatment when compared to placebo. A significantly greater proportion of patients on active treatment reported a more than 30% reduction in mean pain intensity score compared to baseline (i.e. responder rate) meeting a key secondary endpoint. EMA 401 was generally safe and well tolerated with no serious treatment related adverse events reported. Full results of the Phase II trial are expected to be published in a leading pain clinical research journal.